Fimea pharmaceuticals steroids

References
1. Madsen S. Improving access to modern therapies: what can we learn from gainsharing practices? The Scandinavian experience. 15th Biosimilar Medicines Conference. Biosimilar medicines: a game changer for healthcare sustainability; 23−24 March 2017; London, UK.
2. GaBI Online - Generics and Biosimilars Initiative. Norway, biosimilars in different funding systems []. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Oct 20]. Available from: /Biosimilars/Research/Norway-biosimilars-in-different-funding-systems
3. GaBI Online - Generics and Biosimilars Initiative. France to allow biosimilars substitution []. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Oct 20]. Available from: /Policies-Legislation/France-to-allow-biosimilars-substitution
4. GaBI Online - Generics and Biosimilars Initiative. Biosimilar substitution in Europe []. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Oct 20]. Available from: /Reports/Biosimilar-substitution-in-Europe
5. GaBI Online – Generics and Biosimilars Initiative. Finnish drug regulator recommends interchangeability of biosimilars []. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Oct 20]. Available from: /Policies-Legislation/Finnish-drug-regulator-recommends-interchangeability-of-biosimilars
6. FIMEA. Interchangeability of biosimilars – position of Finnish Medicines Agency Fimea. 22 May 2015 [homepage on the Internet]. [cited 2017 Oct 20]. Available from: /documents/542809/838272/29197_Biosimilaarien_vaihtokelpoisuus_
7. GaBI Online – Generics and Biosimilars Initiative. Australia’s PBAC recommends substitution of biosimilars []. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Oct 20]. Available from: /Biosimilars/General/Australia-s-PBAC-recommends-substitution-of-biosimilars
8. GaBI Online – Generics and Biosimilars Initiative. FDA issues draft guidance on biosimilar interchangeability []. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Oct 20]. Available from: /Guidelines/FDA-issues-draft-guidance-on-biosimilar-interchangeability

The material being published is not necessarily complete or up-to-date due to the technical quality of files submitted to the Finnish Medicines Agency (Fimea) or earlier to the National Agency for Medicines (NAM) and the delays in delivery. For this reason, Fimea cannot guarantee that the document on the Internet fully complies with the summary of product characteristics and package leaflet officially approved by a desicion for a marketing authorisation. Only the hard copies of the SPCs and the PLs, which are in accordance with the marketing authorisation granted, are conclusive.

Fimea pharmaceuticals steroids

fimea pharmaceuticals steroids

Media:

fimea pharmaceuticals steroidsfimea pharmaceuticals steroidsfimea pharmaceuticals steroidsfimea pharmaceuticals steroidsfimea pharmaceuticals steroids

http://buy-steroids.org